{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:29:23Z","timestamp":1794047363465,"version":"4.8.0"},"reference-count":32,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"7","license":[{"start":{"date-parts":[[2020,7,30]],"date-time":"2020-07-30T00:00:00Z","timestamp":1596067200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Hemophagocytic lymphohistiocytosis (HLH) is an immune-regulatory disorder characterized by excessive production of inflammatory cytokines. The treatment recommendations of the HLH-1994 and HLH-2004 protocols have long been used in HLH therapy, but some patients still do not respond well to or have unacceptable side effects from conventional therapies. It is believed that cytokine-targeted strategies that directly target disease-driving pathways will be promising options for HLH. This prospective study aimed to investigate the efficacy and safety of ruxolitinib, a Janus kinase (JAK) 1\/2 inhibitor, as a front-line therapy in children with secondary HLH. Twelve newly diagnosed patients without previous treatment were enrolled in this study with a median follow-up of 8.2 (7.1-12.0) months, including 8 cases of Epstein-Barr virus associated HLH (EBV-HLH), 2 cases of autoinflammatory disorder (AID)- associated HLH, and 2 cases of unknown etiology. Patients received oral ruxolitinib dosed on 2.5 mg, 5 mg or 10 mg twice daily depending on the body weight for 28 consecutive days. The overall response rate at the end of treatment (day 28) was 83.3% (10\/12), with 66.7% (8\/12) in complete response (CR), 8.3% (1\/12) in partial response (PR), and 8.3% (1\/12) in HLH improvement. Among the patients achieving CR, 87.5% (7\/8) maintained CR condition for&gt;6 months, and one patient with EBV-HLH relapsed following CR. For the EBV-HLH subgroup, all 8 patients responded to ruxolitinib, with a CR rate of 75% and a PR rate of 25%. Two patients with AID-associated HLH had quite different responses, with one showing reversal of the HLH abnormalities soon and the other showing no improvement, as did the two cases of unknown etiology. Patients who had no response or discontinued ruxolitinib all responded well to the subsequent HLH-1994 regimen. The expected 6-month event-free survival (EFS) rate was 58.3%\u00b110.2%. No serious adverse effects were reported. Our study provides further support for the possibility of ruxolitinib targeted therapy for secondary HLH in children. This study was registered in the Chinese Clinical Trials Registry Platform (http:\/\/www.chictr.org.cn\/) as ChiCTR2000029977.<\/jats:p>","DOI":"10.3324\/haematol.2020.253781","type":"journal-article","created":{"date-parts":[[2020,7,30]],"date-time":"2020-07-30T14:57:04Z","timestamp":1596121024000},"page":"1892-1901","source":"Crossref","is-referenced-by-count":52,"title":["A pilot study of ruxolitinib as a front-line therapy for 12 children with secondary hemophagocytic lymphohistiocytosis"],"prefix":"10.3324","volume":"106","author":[{"family":"Qing Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Ang Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Hong-Hao Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Li Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Hong-Yun Lian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Dong Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Yun-Ze Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Lei Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Wei-Jing Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Ying Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Tian-You Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Zhi-Gang Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Rui Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2020,7,30]]},"reference":[{"key":"27179","doi-asserted-by":"crossref","unstructured":"Thomas W, Veer MV, Besser M. Haemophagocytic lymphohistiocytosis: an elusive syndrome. Clin Med (Lond). 2016; 16(5):432-436.","DOI":"10.7861\/clinmedicine.16-5-432"},{"key":"27180","doi-asserted-by":"crossref","unstructured":"Trottestam H, Horne A, Aric\u00f2 M. Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol. Blood. 2011; 118(17):4577-4584.","DOI":"10.1182\/blood-2011-06-356261"},{"key":"27181","doi-asserted-by":"crossref","unstructured":"Bergsten E, Horne A, Aric\u00f3 M. Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study. Blood. 2017; 130(25):2728-2738.","DOI":"10.1182\/blood-2017-06-788349"},{"key":"27182","doi-asserted-by":"crossref","unstructured":"Pui CH, Ribeiro RC, Hancock ML. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med. 1991; 325(24):1682-1687.","DOI":"10.1056\/NEJM199112123252402"},{"key":"27183","doi-asserted-by":"crossref","unstructured":"Henter JI, Elinder G, L\u00fcbeck PO, Ost A. Myelodysplastic syndrome following epipodophyllotoxin therapy in familial hemophagocytic lymphohistiocytosis. Pediatr Hematol Oncol. 1993; 10(2):163-168.","DOI":"10.3109\/08880019309016551"},{"key":"27184","doi-asserted-by":"crossref","unstructured":"Kitazawa J, Ito E, Arai K, Yokoyama M, Fukayama M, Imashuku S. Secondary acute myelocytic leukemia after successful chemotherapy with etoposide for Epstein- Barr virus-associated hemophagocytic lymphohistiocytosis. Med Pediatr Oncol. 2001; 37(2):153-154.","DOI":"10.1002\/mpo.1189"},{"key":"27185","doi-asserted-by":"crossref","unstructured":"Miettunen PM, Narendran A, Jayanthan A, Behrens EM, Cron RQ. Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients. Rheumatology (Oxford). 2011; 50(2):417-419.","DOI":"10.1093\/rheumatology\/keq218"},{"key":"27186","doi-asserted-by":"crossref","unstructured":"Locatelli F, Jordan MB, Allen C. Emapalumab in children with primary hemophagocytic lymphohistiocytosis. N Engl J Med. 2020; 382(19):1811-1822.","DOI":"10.1056\/NEJMoa1911326"},{"key":"27187","doi-asserted-by":"crossref","unstructured":"Villarino AV, Kanno Y, Ferdinand JR, O'Shea JJ. Mechanisms of Jak\/STAT signaling in immunity and disease. J Immunol. 2015; 194(1):21-27.","DOI":"10.4049\/jimmunol.1401867"},{"key":"27188","doi-asserted-by":"crossref","unstructured":"Kiu H, Nicholson SE. Biology and significance of the JAK\/STAT signalling pathways. Growth Factors. 2012; 30(2):88-106.","DOI":"10.3109\/08977194.2012.660936"},{"key":"27189","doi-asserted-by":"crossref","unstructured":"Das R, Guan P, Sprague L. Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis. Blood. 2016; 127(13):1666-1675.","DOI":"10.1182\/blood-2015-12-684399"},{"key":"27190","doi-asserted-by":"crossref","unstructured":"Maschalidi S, Sepulveda FE, Garrigue A, Fischer A, de Saint Basile G. Therapeutic effect of JAK1\/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice. Blood. 2016; 128(1):60-71.","DOI":"10.1182\/blood-2016-02-700013"},{"key":"27191","doi-asserted-by":"crossref","unstructured":"Albeituni S, Verbist KC, Tedrick PE. Mechanisms of action of ruxolitinib in murine models of hemophagocytic lymphohistiocytosis. Blood. 2019; 134(2):147-159.","DOI":"10.1182\/blood.2019000761"},{"key":"27192","doi-asserted-by":"crossref","unstructured":"Sin JH, Zangardi ML. Ruxolitinib for secondary hemophagocytic lymphohistiocytosis: first case report. Hematol Oncol Stem Cell Ther. 2019; 12(3):166-170.","DOI":"10.1016\/j.hemonc.2017.07.002"},{"key":"27193","doi-asserted-by":"crossref","unstructured":"Broglie L, Pommert L, Rao S. Ruxolitinib for treatment of refractory hemophagocytic lymphohistiocytosis. Blood Adv. 2017; 1(19):1533-1536.","DOI":"10.1182\/bloodadvances.2017007526"},{"key":"27194","doi-asserted-by":"crossref","unstructured":"Wang J, Wang Y, Wu L. Ruxolitinib for refractory\/relapsed hemophagocytic lymphohistiocytosis. Haematologica. 2020; 105(5):e210-e212.","DOI":"10.3324\/haematol.2019.222471"},{"key":"27195","doi-asserted-by":"crossref","unstructured":"Slostad J, Hoversten P, Haddox CL, Cisak K, Paludo J, Tefferi A. Ruxolitinib as first-line treatment in secondary hemophagocytic lymphohistiocytosis: a single patient experience. Am J Hematol. 2018; 93(2):E47-e49.","DOI":"10.1002\/ajh.24971"},{"key":"27196","doi-asserted-by":"crossref","unstructured":"Zandvakili I, Conboy CB, Ayed AO, Cathcart-Rake EJ, Tefferi A. Ruxolitinib as first-line treatment in secondary hemophagocytic lymphohistiocytosis: a second experience. Am J Hematol. 2018; 93(5):E123-e125.","DOI":"10.1002\/ajh.25063"},{"key":"27197","doi-asserted-by":"crossref","unstructured":"Ahmed A, Merrill SA, Alsawah F. Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial. Lancet Haematol. 2019; 6(12):e630-e637.","DOI":"10.1016\/S2352-3026(19)30156-5"},{"key":"27198","doi-asserted-by":"crossref","unstructured":"Henter JI, Horne A, Aric\u00f3 M. HLH- 2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediat Blood Cancer. 2007; 48(2):124-131.","DOI":"10.1002\/pbc.21039"},{"key":"27199","doi-asserted-by":"crossref","unstructured":"Marsh RA, Allen CE, McClain KL. Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab. Pediat Blood Cancer. 2013; 60(1):101-109.","DOI":"10.1002\/pbc.24188"},{"key":"27200","doi-asserted-by":"crossref","unstructured":"Marsh RA, Jordan MB, Talano JA. Salvage therapy for refractory hemophagocytic lymphohistiocytosis: a review of the published experience. Pediat Blood Cancer. 2017; 64(4)","DOI":"10.1002\/pbc.26308"},{"key":"27201","doi-asserted-by":"crossref","unstructured":"Lounder DT, Bin Q, de Min C, Jordan MB. Treatment of refractory hemophagocytic lymphohistiocytosis with emapalumab despite severe concurrent infections. Blood Adv. 2019; 3(1):47-50.","DOI":"10.1182\/bloodadvances.2018025858"},{"key":"27202","doi-asserted-by":"crossref","unstructured":"Verstovsek S, Mesa RA, Gotlib J. A double- blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012; 366(9):799-807.","DOI":"10.1056\/NEJMoa1110557"},{"key":"27203","doi-asserted-by":"crossref","unstructured":"Vannucchi AM, Kiladjian JJ, Griesshammer M. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015; 372(5):426-435.","DOI":"10.1056\/NEJMoa1409002"},{"key":"27204","doi-asserted-by":"crossref","unstructured":"Przepiorka D, Luo L, Subramaniam S. FDA approval summary: ruxolitinib for treatment of steroid-refractory acute graft-versushost disease. Oncologist. 2020; 25(2):e328-e334.","DOI":"10.1634\/theoncologist.2019-0627"},{"key":"27205","doi-asserted-by":"crossref","unstructured":"Zeiser R, Burchert A, Lengerke C. Ruxolitinib in corticosteroid-refractory graftversus- host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia. 2015; 29(10):2062-2068.","DOI":"10.1038\/leu.2015.212"},{"key":"27206","doi-asserted-by":"crossref","unstructured":"Pemmaraju N, Kantarjian H, Kadia T. A phase I\/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2015; 15(3):171-176.","DOI":"10.1016\/j.clml.2014.08.003"},{"key":"27207","doi-asserted-by":"crossref","unstructured":"Dao KT, Gotlib J, Deininger MMN. Efficacy of ruxolitinib in patients with chronic neutrophilic leukemia and atypical chronic myeloid leukemia. J Clin Oncol. 2020; 38(10):1006-1018.","DOI":"10.1200\/JCO.19.00895"},{"key":"27208","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez Vicent M, Molina B, Gonz\u00e1lez de Pablo J, Castillo A, D\u00edaz M. Ruxolitinib treatment for steroid refractory acute and chronic graft vs host disease in children: Clinical and immunological results. Am J Hematol. 2019; 94(3):319-326.","DOI":"10.1002\/ajh.25376"},{"key":"27209","doi-asserted-by":"crossref","unstructured":"Wang J, Wang Y, Wu L, Zhang J, Lai W, Wang Z. PEG-aspargase and DEP regimen combination therapy for refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. J Hematol Oncol. 2016; 9(1):84.","DOI":"10.1186\/s13045-016-0317-7"},{"key":"27210","doi-asserted-by":"crossref","unstructured":"Li H, Liu S, Hu J. Epstein-Barr virus lytic reactivation regulation and its pathogenic role in carcinogenesis. Int J Biol Sci. 2016; 12(11):1309-1318.","DOI":"10.7150\/ijbs.16564"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/9827\/71102","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/9827\/71103","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/9827\/71102","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T09:57:49Z","timestamp":1794045469000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/9827"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,30]]},"references-count":32,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,7,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2020.253781","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7,30]]}}}